forecast glp-1 prescriptions growth 2025 Drugs: Pulse Survey (U.S.) GLP-1 Weight Loss Drug Market

FDA-approved GLP-1 receptor agonists include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), exenatide (Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist

People who have difficulty with self-injection due to physical limitations

It is important to note that severe gastrointestinal side effects can lead to dehydration, which may affect kidney function

The GLP-1 companion-supplement market was valued at roughly $735 million in the US in 2025 and is projected to keep growing at a double-digit annual rate through the early 2030s

FAQ Can Ozempic cause a diverticulitis flare